Haylea A Hannah1, Roque Miramontes2, Neel R Gandhi1. 1. 1 Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA. 2. 2 Division of Tuberculosis Elimination, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Abstract
OBJECTIVES: The objectives of our study were (1) to determine risk factors associated with tuberculosis (TB)-specific and non-TB-specific mortality among patients with TB and (2) to examine whether risk factors for TB-specific mortality differed from those for non-TB-specific mortality. METHODS: We obtained data from the National Tuberculosis Surveillance System and included all patients who had TB between 2009 and 2013 in the United States and its territories. We used multinomial logistic regression analysis to determine the adjusted odds ratio (aOR) of each risk factor for TB-specific and non-TB-specific mortality. RESULTS: Of 52 175 eligible patients with TB, 1404 died from TB, and 2413 died from other causes. Some of the risk factors associated with the highest odds of TB-specific mortality were multidrug-resistant TB diagnosis (aOR = 3.42; 95% CI, 1.95-5.99), end-stage renal disease (aOR = 3.02; 95% CI, 2.23-4.08), human immunodeficiency virus infection (aOR = 2.63; 95% CI, 2.02-3.42), age 45-64 years (aOR = 2.57; 95% CI, 2.01-3.30) or age ≥65 years (aOR = 5.76; 95% CI, 4.37-7.61), and immunosuppression (aOR = 2.20; 95% CI, 1.71-2.83). All of these risk factors except multidrug-resistant TB were also associated with increased odds of non-TB-specific mortality. CONCLUSION: TB patients with certain risk factors have an elevated risk of TB-specific mortality and should be monitored before, during, and after treatment. Identifying the predictors of TB-specific mortality may help public health authorities determine which subpopulations to target and where to allocate resources.
OBJECTIVES: The objectives of our study were (1) to determine risk factors associated with tuberculosis (TB)-specific and non-TB-specific mortality among patients with TB and (2) to examine whether risk factors for TB-specific mortality differed from those for non-TB-specific mortality. METHODS: We obtained data from the National Tuberculosis Surveillance System and included all patients who had TB between 2009 and 2013 in the United States and its territories. We used multinomial logistic regression analysis to determine the adjusted odds ratio (aOR) of each risk factor for TB-specific and non-TB-specific mortality. RESULTS: Of 52 175 eligible patients with TB, 1404 died from TB, and 2413 died from other causes. Some of the risk factors associated with the highest odds of TB-specific mortality were multidrug-resistant TB diagnosis (aOR = 3.42; 95% CI, 1.95-5.99), end-stage renal disease (aOR = 3.02; 95% CI, 2.23-4.08), human immunodeficiency virus infection (aOR = 2.63; 95% CI, 2.02-3.42), age 45-64 years (aOR = 2.57; 95% CI, 2.01-3.30) or age ≥65 years (aOR = 5.76; 95% CI, 4.37-7.61), and immunosuppression (aOR = 2.20; 95% CI, 1.71-2.83). All of these risk factors except multidrug-resistant TB were also associated with increased odds of non-TB-specific mortality. CONCLUSION: TB patients with certain risk factors have an elevated risk of TB-specific mortality and should be monitored before, during, and after treatment. Identifying the predictors of TB-specific mortality may help public health authorities determine which subpopulations to target and where to allocate resources.
Authors: T R Sterling; Z Zhao; A Khan; R E Chaisson; N Schluger; B Mangura; M Weiner; A Vernon Journal: Int J Tuberc Lung Dis Date: 2006-05 Impact factor: 2.373
Authors: Ekaterina V Kourbatova; Michael K Leonard; Javier Romero; Colleen Kraft; Carlos del Rio; Henry M Blumberg Journal: Eur J Epidemiol Date: 2006-10-27 Impact factor: 8.082
Authors: David J Horne; Rebecca Hubbard; Masahiro Narita; Alexia Exarchos; David R Park; Christopher H Goss Journal: BMC Infect Dis Date: 2010-08-27 Impact factor: 3.090
Authors: Meghan A Baker; Anthony D Harries; Christie Y Jeon; Jessica E Hart; Anil Kapur; Knut Lönnroth; Salah-Eddine Ottmani; Sunali D Goonesekera; Megan B Murray Journal: BMC Med Date: 2011-07-01 Impact factor: 8.775
Authors: Andrew J Karter; Dean Schillinger; Alyce S Adams; Howard H Moffet; Jennifer Liu; Nancy E Adler; Alka M Kanaya Journal: Diabetes Care Date: 2012-10-15 Impact factor: 19.112
Authors: Matthew J Magee; Argita D Salindri; Nang Thu Thu Kyaw; Sara C Auld; J Sonya Haw; Guillermo E Umpierrez Journal: Curr Diab Rep Date: 2018-08-09 Impact factor: 4.810
Authors: Suzanne F Beavers; Lisa Pascopella; Amy L Davidow; Joan M Mangan; Yael R Hirsch-Moverman; Jonathan E Golub; Henry M Blumberg; Risa M Webb; Rachel A Royce; Susan E Buskin; Michael K Leonard; Paul C Weinfurter; Robert W Belknap; Stephen E Hughes; Jon V Warkentin; Sharon F Welbel; Thaddeus L Miller; Saini R Kundipati; Michael Lauzardo; Pennan M Barry; Dolly J Katz; Denise O Garrett; Edward A Graviss; Jennifer M Flood Journal: Ann Am Thorac Soc Date: 2018-06
Authors: Destani J Bizune; Russell R Kempker; Michelle Kagei; Aliya Yamin; Omar Mohamed; David P Holland; Alawode Oladele; Yun F Wang; Paulina A Rebolledo; Henry M Blumberg; Susan M Ray; Marcos C Schechter Journal: AIDS Res Hum Retroviruses Date: 2018-09-11 Impact factor: 2.205
Authors: D T Santos; C Nunes; L S Alves; A A R Queiroz; M J Miranda; L H Arroyo; M Yamamura; A S Belchior; M P Popolin; M A M Arcoverde; T Z Berra; A C V Ramos; I C Pinto; P F Palha; B M A Gabardo; E M Dessunti; R A Arcêncio Journal: Epidemiol Infect Date: 2018-07-11 Impact factor: 4.434
Authors: Peter Seah Keng Tok; Su May Liew; Li Ping Wong; Asmah Razali; Tharani Loganathan; Karuthan Chinna; Nurhuda Ismail; Naim Abdul Kadir Journal: PLoS One Date: 2020-04-22 Impact factor: 3.240
Authors: Marcos C Schechter; Destani Bizune; Michelle Kagei; Mamuka Machaidze; David P Holland; Alawode Oladele; Yun F Wang; Paulina A Rebolledo; Susan M Ray; Russell R Kempker Journal: Clin Infect Dis Date: 2017-11-13 Impact factor: 9.079
Authors: A González-García; L Carpintero; J Fortún; E Navas-Elorza; P Martín-Dávila; S Moreno Journal: Rev Esp Quimioter Date: 2018-07-02 Impact factor: 1.553